331 related articles for article (PubMed ID: 32219902)
1. Polyomavirus-driven Merkel cell carcinoma: Prospects for therapeutic vaccine development.
Tabachnick-Cherny S; Pulliam T; Church C; Koelle DM; Nghiem P
Mol Carcinog; 2020 Jul; 59(7):807-821. PubMed ID: 32219902
[TBL] [Abstract][Full Text] [Related]
2. Merkel cell polyomavirus-specific CD8⁺ and CD4⁺ T-cell responses identified in Merkel cell carcinomas and blood.
Iyer JG; Afanasiev OK; McClurkan C; Paulson K; Nagase K; Jing L; Marshak JO; Dong L; Carter J; Lai I; Farrar E; Byrd D; Galloway D; Yee C; Koelle DM; Nghiem P
Clin Cancer Res; 2011 Nov; 17(21):6671-80. PubMed ID: 21908576
[TBL] [Abstract][Full Text] [Related]
3. Prevalent and Diverse Intratumoral Oncoprotein-Specific CD8
Jing L; Ott M; Church CD; Kulikauskas RM; Ibrani D; Iyer JG; Afanasiev OK; Colunga A; Cook MM; Xie H; Greninger AL; Paulson KG; Chapuis AG; Bhatia S; Nghiem P; Koelle DM
Cancer Immunol Res; 2020 May; 8(5):648-659. PubMed ID: 32179557
[TBL] [Abstract][Full Text] [Related]
4. Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes.
Colunga A; Pulliam T; Nghiem P
Clin Cancer Res; 2018 May; 24(9):2035-2043. PubMed ID: 29217527
[TBL] [Abstract][Full Text] [Related]
5. Merkel cell polyomavirus-specific immune responses in patients with Merkel cell carcinoma receiving anti-PD-1 therapy.
Miller NJ; Church CD; Fling SP; Kulikauskas R; Ramchurren N; Shinohara MM; Kluger HM; Bhatia S; Lundgren L; Cheever MA; Topalian SL; Nghiem P
J Immunother Cancer; 2018 Nov; 6(1):131. PubMed ID: 30482247
[TBL] [Abstract][Full Text] [Related]
6. Quality Is King: Fundamental Insights into Tumor Antigenicity from Virus-Associated Merkel Cell Carcinoma.
Lahman MC; Paulson KG; Nghiem PT; Chapuis AG
J Invest Dermatol; 2021 Aug; 141(8):1897-1905. PubMed ID: 33863500
[TBL] [Abstract][Full Text] [Related]
7. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer.
Bhatia S; Afanasiev O; Nghiem P
Curr Oncol Rep; 2011 Dec; 13(6):488-97. PubMed ID: 21953511
[TBL] [Abstract][Full Text] [Related]
8. Advances in Immunotherapy for Metastatic Merkel Cell Carcinoma: A Clinician's Guide.
Paulson KG; Bhatia S
J Natl Compr Canc Netw; 2018 Jun; 16(6):782-790. PubMed ID: 29891528
[TBL] [Abstract][Full Text] [Related]
9. Insights into anti-tumor immunity
Jani S; Church CD; Nghiem P
Front Immunol; 2023; 14():1172913. PubMed ID: 37287968
[TBL] [Abstract][Full Text] [Related]
10. Targeting Merkel Cell Carcinoma by Engineered T Cells Specific to T-Antigens of Merkel Cell Polyomavirus.
Gavvovidis I; Leisegang M; Willimsky G; Miller N; Nghiem P; Blankenstein T
Clin Cancer Res; 2018 Aug; 24(15):3644-3655. PubMed ID: 29669806
[No Abstract] [Full Text] [Related]
11. LAMP1 targeting of the large T antigen of Merkel cell polyomavirus results in potent CD4 T cell responses and tumor inhibition.
Buchta Rosean C; Leyder EC; Hamilton J; Carter JJ; Galloway DA; Koelle DM; Nghiem P; Heiland T
Front Immunol; 2023; 14():1253568. PubMed ID: 37711623
[TBL] [Abstract][Full Text] [Related]
12. Rationale for immune-based therapies in Merkel polyomavirus-positive and -negative Merkel cell carcinomas.
Vandeven N; Nghiem P
Immunotherapy; 2016 Jul; 8(8):907-21. PubMed ID: 27381685
[TBL] [Abstract][Full Text] [Related]
13. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I.
Chapuis AG; Afanasiev OK; Iyer JG; Paulson KG; Parvathaneni U; Hwang JH; Lai I; Roberts IM; Sloan HL; Bhatia S; Shibuya KC; Gooley T; Desmarais C; Koelle DM; Yee C; Nghiem P
Cancer Immunol Res; 2014 Jan; 2(1):27-36. PubMed ID: 24432305
[TBL] [Abstract][Full Text] [Related]
14. Human CD4
Longino NV; Yang J; Iyer JG; Ibrani D; Chow IT; Laing KJ; Campbell VL; Paulson KG; Kulikauskas RM; Church CD; James EA; Nghiem P; Kwok WW; Koelle DM
Cancer Immunol Res; 2019 Oct; 7(10):1727-1739. PubMed ID: 31405946
[TBL] [Abstract][Full Text] [Related]
15. Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer.
Akaike T; Nghiem P
J Dermatol Sci; 2022 Jan; 105(1):2-10. PubMed ID: 34836718
[TBL] [Abstract][Full Text] [Related]
16. Expression of the IDO1/TDO2-AhR pathway in tumor cells or the tumor microenvironment is associated with Merkel cell polyomavirus status and prognosis in Merkel cell carcinoma.
Wardhani LO; Matsushita M; Iwasaki T; Kuwamoto S; Nonaka D; Nagata K; Kato M; Kitamura Y; Hayashi K
Hum Pathol; 2019 Feb; 84():52-61. PubMed ID: 30240768
[TBL] [Abstract][Full Text] [Related]
17. Merkel polyomavirus-specific T cells fluctuate with merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers.
Afanasiev OK; Yelistratova L; Miller N; Nagase K; Paulson K; Iyer JG; Ibrani D; Koelle DM; Nghiem P
Clin Cancer Res; 2013 Oct; 19(19):5351-60. PubMed ID: 23922299
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival.
Lipson EJ; Vincent JG; Loyo M; Kagohara LT; Luber BS; Wang H; Xu H; Nayar SK; Wang TS; Sidransky D; Anders RA; Topalian SL; Taube JM
Cancer Immunol Res; 2013 Jul; 1(1):54-63. PubMed ID: 24416729
[TBL] [Abstract][Full Text] [Related]
19. Merkel cell polyomavirus in Merkel cell carcinogenesis: small T antigen-mediates c-Jun phosphorylation.
Wu JH; Simonette RA; Nguyen HP; Rady PL; Tyring SK
Virus Genes; 2016 Jun; 52(3):397-9. PubMed ID: 26995220
[TBL] [Abstract][Full Text] [Related]
20. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy.
Goh G; Walradt T; Markarov V; Blom A; Riaz N; Doumani R; Stafstrom K; Moshiri A; Yelistratova L; Levinsohn J; Chan TA; Nghiem P; Lifton RP; Choi J
Oncotarget; 2016 Jan; 7(3):3403-15. PubMed ID: 26655088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
